The recently developed GROMOS 54A7 force field, a modification of the 53A6 force field, is validated by simulating the folding equilibrium of two β-peptides which show different dominant folds, i.e., a 314-helix and a hairpin, using three different force fields, i.e., GROMOS 45A3, 53A6, and 54A7. The 54A7 force field stabilizes both folds, and the agreement of the simulated NOE atom-atom distances with the experimental NMR data is slightly improved when using the 54A7 force field, while the agreement of the (3)J couplings with experimental results remains essentially unchanged when varying the force field. The 54A7 force field developed to improve the stability of α-helical structures in proteins can thus be safely used in simulations of β-peptides.
Progress
in the development of GPU-accelerated free energy simulation
software has enabled practical applications on complex biological
systems and fueled efforts to develop more accurate and robust predictive
methods. In particular, this work re-examines concerted (a.k.a., one-step
or unified) alchemical transformations commonly used in the prediction
of hydration and relative binding free energies (RBFEs). We first
classify several known challenges in these calculations into three
categories: endpoint catastrophes, particle collapse, and large gradient-jumps.
While endpoint catastrophes have long been addressed using softcore
potentials, the remaining two problems occur much more sporadically
and can result in either numerical instability (i.e., complete failure
of a simulation) or inconsistent estimation (i.e., stochastic convergence
to an incorrect result). The particle collapse problem stems from
an imbalance in short-range electrostatic and repulsive interactions
and can, in principle, be solved by appropriately balancing the respective
softcore parameters. However, the large gradient-jump problem itself
arises from the sensitivity of the free energy to large values of
the softcore parameters, as might be used in trying to solve the particle
collapse issue. Often, no satisfactory compromise exists with the
existing softcore potential form. As a framework for solving these
problems, we developed a new family of smoothstep softcore (SSC) potentials
motivated by an analysis of the derivatives along the alchemical path.
The smoothstep polynomials generalize the monomial functions that
are used in most implementations and provide an additional path-dependent
smoothing parameter. The effectiveness of this approach is demonstrated
on simple yet pathological cases that illustrate the three problems
outlined. With appropriate parameter selection, we find that a second-order
SSC(2) potential does at least as well as the conventional approach
and provides vast improvement in terms of consistency across all cases.
Last, we compare the concerted SSC(2) approach against the gold-standard
stepwise (a.k.a., decoupled or multistep) scheme over a large set
of RBFE calculations as might be encountered in drug discovery.
Idiopathic, post-infectious and immunodeficiency constitute major bronchiectasis aetiologies in Guangzhou. Clinical characteristics of patients between known aetiologies and idiopathic bronchiectasis were similar. Ethnicity and geography only account for limited differences in aetiologic spectra. These findings will offer rationales for early diagnosis and management of bronchiectasis in future studies and clinical practice in China.
Free energy perturbation (FEP) has
become widely used in drug discovery
programs for binding affinity prediction between candidate compounds
and their biological targets. However, limitations of FEP applications
also exist, including, but not limited to, high cost, long waiting
time, limited scalability, and breadth of application scenarios. To
overcome these problems, we have developed XFEP, a scalable cloud
computing platform for both relative and absolute free energy predictions
using optimized simulation protocols. XFEP enables large-scale FEP
calculations in a more efficient, scalable, and affordable way, for
example, the evaluation of 5000 compounds can be performed in 1 week
using 50–100 GPUs with a computing cost roughly equivalent
to the cost for the synthesis of only one new compound. By combining
these capabilities with artificial intelligence techniques for goal-directed
molecule generation and evaluation, new opportunities can be explored
for FEP applications in the drug discovery stages of hit identification,
hit-to-lead, and lead optimization based not only on structure exploitation
within the given chemical series but also including evaluation and
comparison of completely unrelated molecules during structure exploration
in a larger chemical space. XFEP provides the basis for scalable FEP
applications to become more widely used in drug discovery projects
and to speed up the drug discovery process from hit identification
to preclinical candidate compound nomination.
Computer simulation using long molecular dynamics (MD) can be used to simulate the folding equilibria of peptides and small proteins. However, a systematic investigation of the influence of the side-chain composition and position at the backbone on the folding equilibrium is computationally as well as experimentally too expensive because of the exponentially growing number of possible side-chain compositions and combinations along the peptide chain. Here, we show that application of the one-step perturbation technique may solve this problem, at least computationally; that is, one can predict many folding equilibria of a polypeptide with different side-chain substitutions from just one single MD simulation using an unphysical reference state. The methodology reduces the number of required separate simulations by an order of magnitude.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.